LOGIN
OTA: Indomethacin is no better than placebo for preventing heterotopic ossification
August 2013
OTA: Indomethacin is no better than placebo for preventing heterotopic ossification
Study Type:Randomized Trial
OE Level Evidence:N/A
Journal Level of Evidence:N/A
Incidence of Posterior Wall Nonunion and Efficacy of Indomethacin Prophylaxis for Heterotopic Ossification After Operative Fixation of Acetabular Fractures: A Randomized Controlled Trial
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
CONFERENCE ACE REPORTS
This ACE Report is a summary of a conference presentation or abstract. The information provided has limited the ability to provide an accurate assessment of the risk of bias or the overall quality. Please interpret the results with caution as trials may be in progress and select results may have been presented.
Synopsis
98 patients with an acetabular fracture were included in a study to examine the effects of indomethacin on the prevention of heterotopic ossification (HO). Patients underwent open reduction and internal fixation through a Kocher-Langenbeck approach. They were then randomized to receive placebo for 6 weeks (group 1), 3 days of indomethacin followed by placebo for a total of 6 weeks (group 2), 1 wee...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.